First administration to humans of a monoclonal antibody cocktail against rabies virus: Safety, tolerability, and neutralizing activity

Vaccine

Volumn 26, Issue 47, 2008, Pages 5922-5927

  Bakker, A B H ^a   Python, C ^b   Kissling, C J ^c   Pandya, P ^d   Marissen, W E ^a   Brink, M F ^a   Lagerwerf, F ^a   Worst, S ^a   van Corven, E ^a   Kostense, S ^a   Hartmann, K ^b   Weverling, G J ^a   Uytdehaag, F ^a   Herzog, C ^b   Briggs, D J ^e   Rupprecht, C E ^f   Grimaldi, R ^a   Goudsmit, J ^a  

^a CRUCELL HOLLAND BV   (Netherlands)

^b Berna Biotech AG   (Switzerland)

^c MDS Inc   (Canada)

^d Dhirubhai Ambani Life Sciences Centre   (India)

^e KANSAS STATE UNIVERSITY   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Equine rabies immunoglobulin (ERIG); Human rabies immunoglobulin (HRIG); Monoclonal antibodies; Post exposure prophylaxis; Rabies; Unmet medical need; Vaccination

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CL184; NEUTRALIZING ANTIBODY; PLACEBO; RABIES IMMUNOGLOBULIN; RABIES VACCINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; INDIA; INJECTION SITE CONTUSION; INJECTION SITE DISCOMFORT; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; LIMB PAIN; LYMPHADENOPATHY; MALE; MENSTRUAL IRREGULARITY; NECK PAIN; NORMAL HUMAN; NOSE CONGESTION; PARAMETER; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROPHYLAXIS; RABIES VIRUS; RABIES VIRUS NEUTRALIZING ACTIVITY; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SINGLE DRUG DOSE; SINUS CONGESTION; SORE THROAT; UNITED STATES; UPPER ABDOMINAL PAIN; VACCINATION; VOMITING;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CELL LINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; RABIES; RABIES VACCINES; RABIES VIRUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 55049129776     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.08.050     Document Type: Article

References (27)

1. Rabies vaccines. WHO position paper. Wkly Epidemiol Rec 82 49/50 (2007) 425-435
2. Dodet B. An important date in rabies history. Vaccine 25 52 (2007) 8647-8650
3. Rupprecht C.E., Hanlon C.A., and Hemachudha T. Rabies re-examined. Lancet Infect Dis 2 6 (2002) 327-343
4. Rupprecht C.E., and Gibbons R.V. Clinical practice. Prophylaxis against rabies. N Engl J Med 351 25 (2004) 2626-2635
5. Wilde H., Khawplod P., Hemachudha T., and Sitprija V. Postexposure treatment of rabies infection: can it be done without immunoglobulin?. Clin Infect Dis 34 4 (2002) 477-480
6. Dodet B. Preventing the incurable: Asian rabies experts advocate rabies control. Vaccine 24 16 (2006) 3045-3049
7. Wilde H. Failures of post-exposure rabies prophylaxis. Vaccine 25 44 (2007) 7605-7609
8. WHO. WHO consultation on a rabies monoclonal antibody cocktail for rabies post exposure treatment. Geneva: WHO, 23-24; May 2002. http://www.who.int/rabies/vaccines/en/mabs_final_report.pdf 2002.
9. Bakker A.B., Marissen W.E., Kramer R.A., Rice A.B., Weldon W.C., Niezgoda M., et al. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J Virol 79 14 (2005) 9062-9068
10. Marissen W.E., Kramer R.A., Rice A., Weldon W.C., Niezgoda M., Faber M., et al. Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis. J Virol 79 8 (2005) 4672-4678
11. Goudsmit J., Marissen W.E., Weldon W.C., Niezgoda M., Hanlon C.A., Rice A.B., et al. Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J Infect Dis 193 6 (2006) 796-801
12. Current WHO guide for rabies pre- and post-exposure treatment in humans. WHO; 2002.
13. Smith J.S., Yader P.A., and Baer G.M. A rapid fluorescent focus inhibition test (RFFIT) for determining rabies virus-neutralizing antibody. In: Meslin F.-X., Kaplan M.M., and Koprowski H. (Eds). Laboratory techniques in rabies. 4th ed. (1996), World Health Organization, Geneva, Switzerland 181-192
14. Sudarshan M.K., Madhusudana S.N., Mahendra B.J., Rao N.S., Ashwath Narayana D.H., Abdul R.S., et al. Assessing the burden of human rabies in India: results of a national multi-center epidemiological survey. Int J Infect Dis 11 1 (2007) 29-35
15. Lang J., Gravenstein S., Briggs D., Miller B., Froeschle J., Dukes C., et al. Evaluation of the safety and immunogenicity of a new, heat-treated human rabies immune globulin using a sham, post-exposure prophylaxis of rabies. Biologicals 26 1 (1998) 7-15
16. Mattner F., Bitz F., Goedecke M., Viertel A., Kuhn S., Gastmeier P., et al. Adverse effects of rabies pre- and postexposure prophylaxis in 290 health-care-workers exposed to a rabies infected organ donor or transplant recipients. Infection 35 4 (2007) 219-224
17. Suwansrinon K., Jaijaroensup W., Daviratanasilpa S., Sriaroon C., Wilde H., and Sitprija V. Adverse reactions to human rabies immune globulin manufactured by the Thai Red Cross Society. Vaccine 23 11 (2005) 1324-1325
18. Quiambao B.P., Lang J., Vital S., Montalban C.G., Le M.V., Wood S.C., et al. Immunogenicity and effectiveness of post-exposure rabies prophylaxis with a new chromatographically purified Vero-cell rabies vaccine (CPRV): a two-stage randomised clinical trial in the Philippines. Acta Trop 75 1 (2000) 39-52
19. Sehgal S., Bhattacharya D., and Bhardwaj M. Ten year longitudinal study of efficacy and safety of purified chick embryo cell vaccine for pre- and post-exposure prophylaxis of rabies in Indian population. J Commun Dis 27 1 (1995) 36-43
20. Ritter G., Cohen L.S., Williams Jr. C., Richards E.C., Old L.J., and Welt S. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res 61 18 (2001) 6851-6859
21. Human rabies prevention-United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 48 RR-1 (1999) 1-21
22. Lang J., Attanath P., Quiambao B., Singhasivanon V., Chanthavanich P., Montalban C., et al. Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine. Acta Trop 70 3 (1998) 317-333
23. Mertz G.J., Nelson K.E., Vithayasai V., Makornkawkeyoon S., Rosanoff E.I., Tint H., et al. Antibody responses to human diploid cell vaccine for rabies with and without human rabies immune globulin. J Infect Dis 145 5 (1982) 720-727
24. Nicholson K.G., and Turner G.S. Studies with human diploid cell strain rabies vaccine and human antirabies immunoglobulin in man. Dev Biol Stand 40 (1978) 115-120
25. Loofbourow J.C., Cabasso V.J., Roby R.E., and Anuskiewicz W. Rabies immune globulin (human). Clinical trials and dose determination. JAMA 217 13 (1971) 1825-1831
26. Aoki F.Y., Rubin M.E., Friesen A.D., Bowman J.M., and Saunders J.R. Intravenous human rabies immunoglobulin for post-exposure prophylaxis: serum rabies neutralizing antibody concentrations and side-effects. J Biol Stand 17 1 (1989) 91-104
27. Lang J., Simanjuntak G.H., Soerjosembodo S., and Koesharyono C. Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post-exposure rabies vaccination under the 2-1-1 regimen: a field trial in Indonesia. MAS054 Clinical Investigator Group. Bull World Health Org 76 5 (1998) 491-495